MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-28-2026
Ascendis Pharma A/S Retained Earnings 2011-2026 | ASND
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Ascendis Pharma A/S
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | -611 M | -393 M | -263 M | 159 M | 111 M | 39.6 M | 2.13 M | -1.95 M | -3.2 M |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 159 M | -611 M | -107 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
NextCure
NXTC
|
-436 M | $ 12.67 | 0.52 % | $ 354 M |  USA |
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Liquidia Corporation
LQDA
|
-626 M | $ 34.25 | -0.38 % | $ 2.23 B | USA |
 |
Shattuck Labs
STTK
|
-431 M | $ 5.02 | 6.13 % | $ 214 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
AbCellera Biologics
ABCL
|
-29.5 M | $ 3.58 | -1.38 % | $ 1.07 B |  Canada |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
ADMA Biologics
ADMA
|
-162 M | $ 15.57 | -5.89 % | $ 3.71 B | USA |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 0.82 | -0.73 % | $ 4.47 M | China |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Anika Therapeutics
ANIK
|
128 M | $ 14.19 | -1.18 % | $ 208 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
-100 M | $ 75.6 | -1.22 % | $ 1.46 B | USA |
 |
Apellis Pharmaceuticals
APLS
|
-3.01 B | $ 20.24 | 1.91 % | $ 2.55 B | USA |
 |
Applied Therapeutics
APLT
|
-469 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
-616 M | - | -13.39 % | $ 1.45 M | USA |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Athersys
ATHX
|
-583 M | - | 3.77 % | $ 22.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-1.1 B | $ 1.5 | -8.28 % | $ 383 M | Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-675 M | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
-1.31 B | $ 159.87 | -2.57 % | $ 7.95 B | USA |
 |
BridgeBio Pharma
BBIO
|
-3.82 B | $ 65.73 | -1.22 % | $ 12.6 B | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
-227 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-256 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-8.32 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellerophon Therapeutics
BLPH
|
-252 M | - | -74.18 % | $ 955 K | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-575 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-362 M | - | -7.31 % | $ 87 M | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M | Canada |
 |
BioLineRx Ltd.
BLRX
|
-278 M | $ 2.72 | -3.31 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
154 M | $ 60.54 | 0.18 % | $ 11.6 B | USA |
 |
CymaBay Therapeutics
CBAY
|
-978 M | - | - | $ 3.45 B | USA |
 |
Codexis
CDXS
|
-563 M | $ 1.25 | 16.2 % | $ 91.8 M | USA |
 |
Cabaletta Bio
CABA
|
-233 M | $ 3.2 | -6.71 % | $ 3.74 M | USA |